On-X Life Technologies, Inc. has completed an analysis comparing the lifetime cost of heart patients choosing an On-X valve versus a stented tissue valve. The Austin-based company has now presented their findings at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, which this year is being held in New Orleans. The analysis will be presented in poster form and, according to an article in The Fort Mills Times:
…the On-X valve is the result of a breakthrough in medical grade carbon technology On-X pure pyrolytic carbon. In addition to providing a more thromboresistant surface, the comparatively high strength of pure On-X Carbon enabled On-X LTI to make significant valve design changes that resulted in a prosthesis that acts more like a natural valve in its treatment of blood. It is well documented that the On-X valve does not produce the turbulence and blood damage commonly produced by other mechanical heart valve prostheses and, therefore, significantly reduces the potential for life-threatening blood clots….[and] the key finding of the study indicates that for a typical 55-year-old heart valve disease patient with a 25-year life expectancy who requires a heart valve replacement, the cumulative healthcare cost savings of using the On-X mechanical valve instead of a stented tissue valve, which may require a replacement with the new transcatheter valve at an advanced age, is approximately $376,000.
The On-X Life cost analysis study was undertaken by Steven D. Culler, Ph.D., of the Rollins School of Public Health at Emory University in Atlanta and Sidney Levitsky, M.D., Harvard Medical School and Beth Israel Deaconess Medical Center, Boston. “This analysis has taken into consideration costs associated with and documented by peer-reviewed publications,” Dr. Culler explains of the process. “These costs include the implantation and lifetime maintenance of the study heart valves, including the cost of treatment of complications for each prosthesis and reoperation over time for stented tissue valves. It is our hope that this analysis may help provide insight into future costs as one aspect of the prosthesis choice decision.” The ISPOR annual meeting will be wrapping up today after a four-day run.